Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells by elevated ROS production

Hyang Sook Seol, Sang Eun Lee, Joon Seon Song, Hye Yong Lee, Sojung Park, Inki Kim, Shree Ram Singh, Suhwan Chang, Se Jin Jang

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Liver cancer is one of the common malignancies in many countries and an increasing cause of cancer death. Despite of that, there are few therapeutic options available with inconsistent outcome, raising a need for developing alternative therapeutic options. Through a drug repositioning screening, we identified and investigated the action mechanism of the Riluzole, an amyotrophic lateral sclerosis (ALS) drug, on hepatocellular carcinoma (HCC) therapy. Treatment of the Riluzole leads to a suppression of cell proliferation in liver primary cancer cells and cancer cell lines. In addition, Riluzole induced caspase-dependent apoptosis and G2/M cell cycle arrest in SNU449 and Huh7 cell lines. In a line with the known function of glutamate release inhibitor, we found Riluzole-treated cells have increased the level of inner cellular glutamate that in turn decrease the glutathione (GSH) level and finally augment the reactive oxygen species (ROS) production. We confirm this finding in vivo by showing the Riluzole-induced GSH and ROS changes in a Huh7 xenograft cancer model. Altogether, these data suggest the anti-cancer effect of Riluzole on hepatocellular carcinoma and the suppression of glutamate signaling might be a new target pathway for HCC therapy.

Original languageEnglish
Pages (from-to)157-165
Number of pages9
JournalCancer Letters
Volume382
Issue number2
DOIs
StatePublished - 28 Nov 2016

Keywords

  • Drug repositioning
  • Hepatocellular carcinoma
  • ROS
  • Riluzole

Fingerprint

Dive into the research topics of 'Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells by elevated ROS production'. Together they form a unique fingerprint.

Cite this